NEW YORK (GenomeWeb) – CareDx said after the close of the market on Monday that its third quarter revenues were up 16 percent year over year.

The Brisbane, Calif.-based molecular diagnostics firm reported total revenues of $6.7 million for the three months ended September 30, up from $5.8 million in the year-ago quarter and just above the consensus analyst estimate of $6.6 million.

Testing revenue increased 16 percent year over year to $6.6 million from $5.7 million, while collaboration and license revenue decreased 42 percent to $53,000 from $91,000.